Results 1 to 10 of about 5,288 (183)

Novel Bruton's tyrosine kinase inhibitor TAS5315 suppresses the progression of inflammation and joint destruction in rodent collagen-induced arthritis. [PDF]

PLoS ONE, 2023
Rheumatoid arthritis is an inflammatory autoimmune disease, characterized by autoantibody production, synovial inflammation, and joint destruction. Its pathogenesis is due to environmental factors and genetic backgrounds.
Daichi Akasaka, Satoru Iguchi, Ryusuke Kaneko, Yohei Yoshiga, Daisuke Kajiwara, Yoshinori Nakachi, Naruto Noma, Kenji Tanaka, Atsushi Shimizu, Fumihito Hosoi   +9 more
doaj   +3 more sources

The Bruton’s Tyrosine Kinase Inhibitor Ibrutinib Impairs the Vascular Development of Zebrafish Larvae [PDF]

Frontiers in Pharmacology, 2021
Ibrutinib is an orally bioavailable, irreversible selective Bruton’s tyrosine kinase inhibitor that has demonstrated impressive therapeutic effects in patients with B cell malignancies.
Kun Wang, Qiushi Xu, Hanbing Zhong
doaj   +2 more sources

HSP90 Inhibitor Ganetespib Enhances the Sensitivity of Mantle Cell Lymphoma to Bruton’s Tyrosine Kinase Inhibitor Ibrutinib [PDF]

Frontiers in Pharmacology, 2022
Mantle cell lymphoma (MCL) is a highly aggressive and heterogeneous B-cell lymphoma. Though Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib has shown great efficacy as a single agent for MCL treatment, the real-world use of ibrutinib is still subject ...
Ziwen Lu, Zhixin Wang, Zhigang Tu, Hanqing Liu   +3 more
doaj   +2 more sources

Fenebrutinib, a Bruton’s tyrosine kinase inhibitor, blocks distinct human microglial signaling pathways [PDF]

Journal of Neuroinflammation
Background Bruton’s tyrosine kinase (BTK) is an intracellular signaling enzyme that regulates B-lymphocyte and myeloid cell functions. Due to its involvement in both innate and adaptive immune compartments, BTK inhibitors have emerged as a therapeutic ...
Julie Langlois, Simona Lange, Martin Ebeling, Will Macnair, Roland Schmucki, Cenxiao Li, Jonathan DeGeer, Tania J. J. Sudharshan, V. Wee Yong, Yun-An Shen, Christopher Harp, Ludovic Collin, James Keaney   +12 more
doaj   +2 more sources

Bruton’s tyrosine kinase inhibitor associated localized extremity edema and erythema [PDF]

JAAD Case Reports
Shannon Meledathu, BS, Paul Chu, MD, Tatyana Feldman, MD, Andre Henri Goy, MD, Rachel Kushner Rosenstein, MD, PhD   +4 more
doaj   +2 more sources

ASK120067 potently suppresses B-cell or T-cell malignancies in vitro and in vivo by inhibiting BTK and ITK

Frontiers in Pharmacology, 2022
Hyperactivation of Bruton’s tyrosine kinase (BTK) or interleukin-2-inducible T cell kinase (ITK) has been attributed to the pathogenesis of B-cell lymphoma or T-cell leukemia, respectively, which suggests that Bruton’s tyrosine kinase and interleukin-2 ...
Peiran Song, Peiran Song, Gang Bai, Shingpan Chan, Tao Zhang, Linjiang Tong, Yi Su, Yanyan Shen, Yi Chen, Yingqiang Liu, Mengzhen Lai, Mengzhen Lai, Yi Ning, Haotian Tang, Yan Fang, Yi Chen, Ke Ding, Jian Ding, Jian Ding, Hua Xie, Hua Xie, Hua Xie   +21 more
doaj   +1 more source

Pseudoangiosarcoma and cutaneous collagenous vasculopathy in a patient on a Bruton’s tyrosine kinase inhibitor [PDF]

JAAD Case Reports
Alison H. Kucharik, MD, Nina B. Curkovic, BS, Julio C. Chavez, MD, Kenneth Y. Tsai, MD, PhD, Andrew S. Brohl, MD, James M. Grichnik, MD, PhD   +5 more
doaj   +2 more sources

A ROR1 small molecule inhibitor (KAN0441571C) induced significant apoptosis of ibrutinib‐resistant ROR1+ CLL cells

eJHaem, 2021
ROR1 – a receptor tyrosine kinase – is overexpressed in CLL. Ibrutinib, a Bruton's tyrosine kinase inhibitor, is clinically effective in CLL but patients may develop resistance. We evaluated the effect of an ROR1 inhibitor, KAN0441571C, in CLL cells from
Amineh Ghaderi, Mohammad‐Ali Okhovat, Layung Sekar Sih Wikanthi, Ann Svensson, Marzia Palma, Johan Schultz, Thomas Olin, Anders Österborg, Håkan Mellstedt, Mohammad Hojjat‐Farsangi   +9 more
doaj   +1 more source

Disseminated fungal infection in a patient receiving zanubrutinib

Clinical Case Reports, 2023
Key Clinical Message We report a case of fatal disseminated aspergillosis in the setting of administration of zanubrutinib, a second‐generation Bruton's tyrosine kinase inhibitor thought to have a lower rate of immunosuppression‐related side effects.
Madalyn Walsh, Alice Xu, Zuhair Ballas, Rolando Sanchez   +3 more
doaj   +1 more source

Spontaneous Spinal Subdural Hematoma Secondary to Hemophilia A and Zanubrutinib

Journal of Neurological Surgery Reports, 2022
Spontaneous spinal subdural hematomas (SSH) are rare occurrences that can occur most commonly secondary to vascular malformations or coagulopathies. Only a small fraction of spontaneous SSHs are caused by acquired coagulation disorders such as leukemia ...
John Lynes, Sebastian Rubino, Andrea Rogers, Sameh Gaballa, Hien D. Liu, John A. Arrington, Edwin Peguero, James K. C. Liu   +7 more
doaj   +3 more sources